Advertisement

Current Psychiatry Reports

, 17:8 | Cite as

Bipolar Disorder: Role of Immune-Inflammatory Cytokines, Oxidative and Nitrosative Stress and Tryptophan Catabolites

  • George Anderson
  • Michael Maes
Bipolar Disorders (W Coryell, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Bipolar Disorders

Abstract

Bipolar disorder (BD) is a complex disorder with a range of presentations. BD is defined by the presentation of symptoms of mania or depression, with classification dependent on patient/family reports and behavioural observations. Recent work has investigated the biological underpinnings of BD, highlighting the role played by increased immune-inflammatory activity, which is readily indicated by changes in pro-inflammatory cytokines or signalling, both centrally and systemically, e.g. increased interleukin-6 trans-signalling. Here, we review the recent data on immune-inflammatory pathways and cytokine changes in BD. Such changes are intimately linked to changes in oxidative and nitrosative stress (O&NS) and neuroregulatory tryptophan catabolites (TRYCATs), both centrally and peripherally. TRYCATs take tryptophan away from serotonin, N-acetylserotonin and melatonin synthesis, driving it down the TRYCAT pathway, predominantly as a result of the pro-inflammatory cytokine induction of indoleamine 2,3-dioxygenase. This has led to an emerging biological perspective on the aetiology, course and treatment of BD. Such data also better integrates the numerous comorbidities associated with BD, including addiction, cardiovascular disorders and increased reporting of pain. Immune-inflammatory, O&NS and TRYCAT pathways are also likely to be relevant biological underpinnings to the significant decrease in life expectancy in BD.

Keywords

Bipolar disorder Depression Mania Oxidative and nitrosative stress Inflammation Melatonin Tryptophan catabolites 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

George Anderson and Michael Maes declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Merinkangas KR, Tohen M. Epidemiology of bipolar disorder in adults and children. In: Tsuang MT, Tohen MT, Jones PB, editors. Textbook in psychiatric epidemiology. Chichester: Wiley; 2011. p. 329–42.CrossRefGoogle Scholar
  2. 2.
    Leussis MP, Madison JM, Petryshen TL. Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology. Biol Mood Anxiety Disord. 2012;2(1):18.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Seifuddin F et al. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):508–18.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Frey BN et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47(4):321–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Maes M et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Maes M et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34(4):301–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Maes M et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66(1):1–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Wadee AA et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson G et al. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep. 2013;65(6):1647–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Maes M et al. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014;18(5):495–512.PubMedCrossRefGoogle Scholar
  11. 11.
    Moylan S et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev. 2014;45:46–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Berk M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Myint AM et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102(1–3):65–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Nievergelt CM et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(3):234–41.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Duffy A et al. Biological indicators of illness risk in offspring of bipolar parents: targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry. 2012;6(2):128–37.PubMedCrossRefGoogle Scholar
  16. 16.••
    Berk M et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16(5):471–7. This is a comprehensive analysis of recent conceptualizations of the neuroprogressive nature of bipolar disorder.PubMedCrossRefGoogle Scholar
  17. 17.
    Gama CS et al. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr. 2013;35(1):70–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: synthesis of the evidence and its clinical application. Aust N Z J Psychiatry. 2013;47(12):1136–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Westman J et al. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;18:3(4).Google Scholar
  20. 20.
    Yee HA, Loh HS, Ng CG. The prevalence and correlates of alcohol use disorder amongst bipolar patients in a hospital setting, Malaysia. Int J Psychiatry Clin Pract. 2013;17(4):292–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiatry Rep. 2014;16(11):499.PubMedCrossRefGoogle Scholar
  22. 22.
    Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl). 2011;214:89–106.CrossRefGoogle Scholar
  23. 23.
    Hamdani N et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8.PubMedCrossRefGoogle Scholar
  24. 24.•
    do Prado CH et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology. 2013;38(5):667–76. This is an interesting article showing significant changes in bipolar patients in regard to immune and intracellular signalling pathways.PubMedCrossRefGoogle Scholar
  25. 25.
    Knijff EM et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006;8(6):740–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Drexhage RC et al. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun. 2011;25(6):1206–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Torres KC et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):229–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Abeer El-Sayed A, Ramy HA. Immunological changes in patients with mania: changes in cell mediated immunity in a sample from Egyptian patients. Egypt J Immunol. 2006;13(1):79–85.Google Scholar
  29. 29.•
    Munkholm K et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119–33. This is an important meta-analysis of cytokine changes in bipolar disorder patients.PubMedCrossRefGoogle Scholar
  30. 30.•
    Modabbernia A et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25. An important meta-analysis of cytokine changes across a range of studies involving bipolar disorder patients.PubMedCrossRefGoogle Scholar
  31. 31.
    Barbosa IG et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci. 2013;263:159–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Barbosa IG et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46:389–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Soeiro-de-Souza MG et al. Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci Lett. 2014;564:111–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Dickerson F et al. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Hsuchou H et al. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem. 2012;30(5):1109–19.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Hope S et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 2013;145(1–3):36–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Remlinger-Molenda A et al. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol. 2012;46(4):599–611.PubMedGoogle Scholar
  38. 38.
    Hsu JW et al. Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study. Bipolar Disord. 2014;16(3):241–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Cetin T et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry. 2012;12:158.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Brietzke E et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Ortiz-Domínguez A et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.PubMedCrossRefGoogle Scholar
  42. 42.
    Becking K et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry. 2013;3:e314.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Bai YM et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 2014;166:187–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Wieck A et al. Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: differential reactivity in bipolar disorder. Neurosci Lett. 2014;580:17–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Barbosa IG et al. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord. 2014;157:41–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Knijff EM et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Kim YK et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1–3):91–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Nassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci. In press.Google Scholar
  49. 49.
    Goldstein BI et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Ch Adol Psychopharmacol. 2011;21:479–84.CrossRefGoogle Scholar
  50. 50.•
    Brambilla P et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry. 2014;4:e406. Important data on changes in monocyte and T cell-associated cytokines in bipolar disorder patients.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Muxel SM et al. NF-kB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-nacetyltransferase (AA-NAT) gene. PLoS ONE. 2012;7(12):e52010.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Barbosa IG et al. Altered intracellular signaling cascades in peripheral blood mononuclear cells from BD patients. J Psychiatr Res. 2013;47(12):1949–54.PubMedCrossRefGoogle Scholar
  53. 53.
    Bartels M et al. Valproic acid treatment is associated with altered leukocyte subset development. J Clin Psychopharmacol. 2012;32(6):832–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Himmerich H et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro. Oxid Med Cell Longev. 2014;2014:806162.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Niles LP et al. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol. 2012;15(9):1343–50.PubMedCrossRefGoogle Scholar
  56. 56.
    Söderlund J et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci. 2011;36(2):114–8.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Shelton RC et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011;16(7):751–62.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Bahna SG et al. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer’s disease. Neurosci Lett. 2014;576:84–7.PubMedCrossRefGoogle Scholar
  59. 59.••
    Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets. 2014;13(5):817–27. An important summary of the potential roles of local melatonin across a host of conditions, including bipolar disorder.PubMedCrossRefGoogle Scholar
  60. 60.
    Lotrich FE et al. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2014;29(6):635–44.PubMedCrossRefGoogle Scholar
  61. 61.
    Doganavsargil-Baysal O et al. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol. 2013;28(2):160–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Volkert J, et al. Evidence for cognitive subgroups in bipolar disorder and the influence of subclinical depression and sleep disturbances. Eur Neuropsychopharmacol. In press.Google Scholar
  63. 63.
    Buoli M et al. The impact of mood episodes and duration of illness on cognition in bipolar disorder. Compr Psychiatry. 2014;55(7):1561–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Rosa AR et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry. 2014;75(5):e450–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Soczynska JK et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med. 2011;13(2):93–116.CrossRefGoogle Scholar
  66. 66.
    Mesman E, et al. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord. In press.Google Scholar
  67. 67.•
    Anderson G, Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Des. 2014;20(23):3812–47. A comprehensive review on the biological changes, and their interconnectedness, occurring in depression.PubMedCrossRefGoogle Scholar
  68. 68.
    Aydemir O, et al. Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr. In press.Google Scholar
  69. 69.•
    Versace A et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry. 2014;19(2):200–8. Important data showing an association of oxidative stress with changes in central white matter.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Andreazza AC et al. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem. 2013;127(4):552–61.PubMedCrossRefGoogle Scholar
  71. 71.•
    Bortolasci CC et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord. 2014;159:23–30. Important data that contributes to the biological differentiation of unipolar and bipolar depression.PubMedCrossRefGoogle Scholar
  72. 72.
    Banerjee U et al. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):56–61.PubMedCrossRefGoogle Scholar
  73. 73.
    Khairova R et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep. 2012;5(3):680–2.PubMedCentralPubMedGoogle Scholar
  74. 74.
    Tan DX et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J Pineal Res. 2013;54(2):127–38.PubMedCrossRefGoogle Scholar
  75. 75.
    Wilson CB et al. Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder. Behav Brain Res. 2014;268:72–80.PubMedCrossRefGoogle Scholar
  76. 76.•
    Soeiro-de-Souza MG et al. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol. 2013;16(7):1505–12. An important article highlighting the changes occurring in neuroprogression in bipolar patients.PubMedCrossRefGoogle Scholar
  77. 77.
    Abe N et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res. 2011;45(8):1106–12.PubMedCrossRefGoogle Scholar
  78. 78.
    Fernandes BS et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995–1004.PubMedCrossRefGoogle Scholar
  79. 79.
    Iuvone PM et al. N-acetylserotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain. Adv Exp Med Biol. 2014;801:765–71.PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Anderson G, Maes M. Metabolic syndrome, Alzheimer’s, schizophrenia and depression: role for leptin, melatonin, kynurenine pathways and neuropeptides. Chap 13. In: Farooqui T, Farooqui AA, editors. Metabolic syndrome and neurological disorders. Chichester, UK: Wiley; 2013.Google Scholar
  81. 81.
    Johansson AS et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res. 2013;47(11):1815–23.PubMedCrossRefGoogle Scholar
  82. 82.
    Lavebratt C et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2014;19(3):334–41.PubMedCrossRefGoogle Scholar
  83. 83.••
    Reininghaus EZ et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014;16(4):432–40. Preliminary data, but potentially of great importance, as the article highlights changes in tryptophan catabolites in bipolar patients.PubMedCrossRefGoogle Scholar
  84. 84.
    Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses. 2011;76:54–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Stubbs B, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand. In press.Google Scholar
  86. 86.
    Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res. 2012;196(2–3):243–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand. 2014;129(2):83–97.PubMedCrossRefGoogle Scholar
  88. 88.
    Hackel D et al. The connection of monocytes and reactive oxygen species in pain. PLoS One. 2013;8(5):e63564.PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.••
    Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett. 2008;29(1):117–24. An article of considerable importance that highlights the role of the gut in driving inflammatory changes in mood disorders.PubMedGoogle Scholar
  90. 90.
    Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. In press.Google Scholar
  91. 91.
    Elamin E et al. Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach. PLoS One. 2014;9(9):e107421.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–9.PubMedGoogle Scholar
  93. 93.
    Sommansson A et al. Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J Physiol Gastrointest Liver Physiol. 2013;305(1):G95–G105.PubMedCrossRefGoogle Scholar
  94. 94.
    Bala S et al. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One. 2014;9(5):e96864.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Etain B et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet. 2012;21(18):4030–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Yu HN et al. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota. Arch Med Res. 2014;45(3):195–20.PubMedCrossRefGoogle Scholar
  97. 97.
    Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Robillard R et al. Sleep-wake cycle and melatonin rhythms in adolescents and young adults with mood disorders: comparison of unipolar and bipolar phenotypes. Eur Psychiatry. 2013;28(7):412–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Markus RP, Cecon E, Pires-Lapa MA. Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci. 2013;14(6):10979–97.PubMedCentralPubMedCrossRefGoogle Scholar
  100. 100.••
    Romo-Nava F et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–21. A very important article showing that melatonin can prevent the inflammatory and metabolic dysregulation associated with antipsychotic treatment of bipolar disorder.PubMedCrossRefGoogle Scholar
  101. 101.
    Redlich R, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression: a voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 2014;71(11):1222–30.Google Scholar
  102. 102.
    Pinato L, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct. In press.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.CRC Scotland & LondonLondonUK
  2. 2.Impact Strategic Treatment CenterDeakin UniversityGeelongAustralia
  3. 3.Department of Psychiatry, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  4. 4.Health Sciences Graduate Program, Health Sciences CenterState University of LondrinaLondrinaBrazil

Personalised recommendations